Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Cited In for PubMed (Select 18316625)


The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice.

Zhang QS, Deater M, Schubert K, Marquez-Loza L, Pelz C, Sinclair DA, Grompe M.

Stem Cell Res. 2015 Jul;15(1):130-40. doi: 10.1016/j.scr.2015.05.007. Epub 2015 May 22.


Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Georgakilas AG, Redon CE, Ferguson NF, Kryston TB, Parekh P, Dickey JS, Nakamura AJ, Mitchell JB, Bonner WM, Martin OA.

Cancer Lett. 2014 Oct 28;353(2):248-57. doi: 10.1016/j.canlet.2014.07.030. Epub 2014 Jul 25.


Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs.

Liu GH, Suzuki K, Li M, Qu J, Montserrat N, Tarantino C, Gu Y, Yi F, Xu X, Zhang W, Ruiz S, Plongthongkum N, Zhang K, Masuda S, Nivet E, Tsunekawa Y, Soligalla RD, Goebl A, Aizawa E, Kim NY, Kim J, Dubova I, Li Y, Ren R, Benner C, del Sol A, Bueren J, Trujillo JP, Surralles J, Cappelli E, Dufour C, Esteban CR, Izpisua Belmonte JC.

Nat Commun. 2014 Jul 7;5:4330. doi: 10.1038/ncomms5330.


Oxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemia.

Li J, Pang Q.

Antioxid Redox Signal. 2014 May 10;20(14):2290-301. doi: 10.1089/ars.2013.5715. Epub 2014 Mar 11. Review.


Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model.

Zhang QS, Marquez-Loza L, Sheehan AM, Watanabe-Smith K, Eaton L, Benedetti E, Major A, Schubert K, Deater M, Joseph E, Grompe M.

Pediatr Blood Cancer. 2014 Apr;61(4):740-2. doi: 10.1002/pbc.24780. Epub 2013 Sep 20.


Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice.

Zhang QS, Watanabe-Smith K, Schubert K, Major A, Sheehan AM, Marquez-Loza L, Newell AE, Benedetti E, Joseph E, Olson S, Grompe M.

Stem Cell Res. 2013 Sep;11(2):687-92. doi: 10.1016/j.scr.2013.04.010. Epub 2013 Apr 30.


Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models.

Bakker ST, de Winter JP, te Riele H.

Dis Model Mech. 2013 Jan;6(1):40-7. doi: 10.1242/dmm.009795. Review.


Molecular pathogenesis and clinical management of Fanconi anemia.

Kee Y, D'Andrea AD.

J Clin Invest. 2012 Nov;122(11):3799-806. doi: 10.1172/JCI58321. Epub 2012 Nov 1. Review.


The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation.

Mitchell JB, Anver MR, Sowers AL, Rosenberg PS, Figueroa M, Thetford A, Krishna MC, Albert PS, Cook JA.

Cancer Res. 2012 Sep 15;72(18):4846-55. doi: 10.1158/0008-5472.CAN-12-1879. Epub 2012 Jul 17.


Strategies for discovery of small molecule radiation protectors and radiation mitigators.

Greenberger JS, Clump D, Kagan V, Bayir H, Lazo JS, Wipf P, Li S, Gao X, Epperly MW.

Front Oncol. 2012 Jan 13;1:59. doi: 10.3389/fonc.2011.00059. eCollection 2011.


Improvement of genetic stability in lymphocytes from Fanconi anemia patients through the combined effect of α-lipoic acid and N-acetylcysteine.

Ponte F, Sousa R, Fernandes AP, Gonçalves C, Barbot J, Carvalho F, Porto B.

Orphanet J Rare Dis. 2012 May 16;7:28. doi: 10.1186/1750-1172-7-28.


SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.

Thomas R, Sharifi N.

Mol Cancer Ther. 2012 Jan;11(1):87-97. doi: 10.1158/1535-7163.MCT-11-0540. Epub 2011 Dec 15.


GS-nitroxide (JP4-039)-mediated radioprotection of human Fanconi anemia cell lines.

Bernard ME, Kim H, Berhane H, Epperly MW, Franicola D, Zhang X, Houghton F, Shields D, Wang H, Bakkenist CJ, Frantz MC, Forbeck EM, Goff JP, Wipf P, Greenberger JS.

Radiat Res. 2011 Nov;176(5):603-12. Epub 2011 Sep 22.


Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells.

Flores-Santana W, Moody T, Chen W, Gorczynski MJ, Shoman ME, Velázquez C, Thetford A, Mitchell JB, Cherukuri MK, King SB, Wink DA.

Br J Pharmacol. 2012 Feb;165(4b):1058-67. doi: 10.1111/j.1476-5381.2011.01527.x.


Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol.

Zhang QS, Marquez-Loza L, Eaton L, Duncan AW, Goldman DC, Anur P, Watanabe-Smith K, Rathbun RK, Fleming WH, Bagby GC, Grompe M.

Blood. 2010 Dec 9;116(24):5140-8. doi: 10.1182/blood-2010-04-278226. Epub 2010 Sep 8.


Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1.

Deng Y, Liu J, Han G, Lu SL, Wang SY, Malkoski S, Tan AC, Deng C, Wang XJ, Zhang Q.

Oncogene. 2010 Dec 16;29(50):6603-8. doi: 10.1038/onc.2010.406. Epub 2010 Sep 6.


Susceptibility pathways in Fanconi's anemia and breast cancer.

D'Andrea AD.

N Engl J Med. 2010 May 20;362(20):1909-19. doi: 10.1056/NEJMra0809889. Review. No abstract available.


Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, Winstanley JH, Barraclough DL, Barraclough R, West CR, Jones NJ.

Am J Pathol. 2010 Jun;176(6):2935-47. doi: 10.2353/ajpath.2010.090779. Epub 2010 Apr 2.


Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Wilcox CS.

Pharmacol Ther. 2010 May;126(2):119-45. doi: 10.1016/j.pharmthera.2010.01.003. Epub 2010 Feb 11. Review.


Fanconi anemia proteins and endogenous stresses.

Pang Q, Andreassen PR.

Mutat Res. 2009 Jul 31;668(1-2):42-53.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk